BR0317099A - Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica - Google Patents

Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica

Info

Publication number
BR0317099A
BR0317099A BR0317099-3A BR0317099A BR0317099A BR 0317099 A BR0317099 A BR 0317099A BR 0317099 A BR0317099 A BR 0317099A BR 0317099 A BR0317099 A BR 0317099A
Authority
BR
Brazil
Prior art keywords
vitro
function
proliferation
tyrosine kinase
inhibit
Prior art date
Application number
BR0317099-3A
Other languages
English (en)
Inventor
Robert A Kirken
Barry D Kahan
Stanislaw M Stepkowski
Waldemar Priebe
Izabela Fokt
Szymon Kosinski
Original Assignee
Boardd Of Regents Of The Unive
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boardd Of Regents Of The Unive filed Critical Boardd Of Regents Of The Unive
Publication of BR0317099A publication Critical patent/BR0317099A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/12—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"MéTODO IN VITRO PARA INIBIR A FUNçãO E/OU PROLIFERAçãO DE UMA JANUS TIROSINA QUINASE 3, MéTODO DE TESTE IN VITRO PARA AUXILIAR NA IDENTIFICAçãO DE SUBSTâNCIAS QUE SãO úTEIS COMO IMUNOSSUPRESSORES TERAPêUTICOS, MéTODO IN VITRO PAPA AUXILIAR NA IDENTIFICAçãO DE UM NOVO MEDICAMENTO IMUNOSSUPRESSOR, MéTODO IN VITRO PARA INIBIR A FUNçãO E/OU PROLIFERAçãO DE UMA CéLULA EXPRESSANDO A JANUS TIROSINA QUINASE 3, USO DE PELO MENOS UM COMPOSTO, COMPOSTO QUìMICO ISOLADO OU PURIFICADO E COMPOSIçãO FARMACêUTICA". São descritos métodos para inibir ou romper a Janus tirosina quinase 3 (Jak3), dependente da função das células de origem linfóide ou mielóide, especialmente para bloquear a proliferação e função dos linfóticos (p.ex., células-T, células-B). é empregado um composto base de Mannich, ou um derivativo ou composto modificado, que é capaz de seletivamente inibir Jak3, enquanto afetando outras atividades da proteína tirosina quinase em uma menor extensão ou não em absoluto, para fornecer efeitos benéficos, tais como mitigação de rejeição de transplante e alívio de respostas alérgicas, com menos efeitos colaterais do que com os agentes imunossupressores convencionais.
BR0317099-3A 2002-12-09 2003-12-09 Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica BR0317099A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43185102P 2002-12-09 2002-12-09
PCT/US2003/038993 WO2004052359A1 (en) 2002-12-09 2003-12-09 Methods for selectively inhibiting janus tyrosine kinase 3 (jak3)

Publications (1)

Publication Number Publication Date
BR0317099A true BR0317099A (pt) 2005-10-25

Family

ID=32507812

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317099-3A BR0317099A (pt) 2002-12-09 2003-12-09 Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica

Country Status (17)

Country Link
US (2) US7365096B2 (pt)
EP (1) EP1578411A4 (pt)
JP (1) JP2006514021A (pt)
KR (1) KR20050084224A (pt)
CN (1) CN1747729A (pt)
AU (1) AU2003297740B2 (pt)
BR (1) BR0317099A (pt)
CA (1) CA2506432A1 (pt)
EC (1) ECSP055843A (pt)
HU (1) HUP0500844A2 (pt)
MX (1) MXPA05006133A (pt)
NO (1) NO20052497L (pt)
NZ (1) NZ540427A (pt)
PL (1) PL376844A1 (pt)
RU (1) RU2005121672A (pt)
WO (1) WO2004052359A1 (pt)
ZA (1) ZA200504163B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087673A2 (en) 2003-03-28 2004-10-14 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
EP1755680A1 (en) * 2004-05-03 2007-02-28 Novartis AG Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
WO2006034478A2 (en) * 2004-09-23 2006-03-30 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
WO2007027238A2 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
TR201802449T4 (tr) 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
NZ568182A (en) 2005-11-21 2010-08-27 Novartis Ag Neuroendocrine tumor treatment using MTOR inhibitors
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2010528086A (ja) 2007-05-29 2010-08-19 ノバルティス アーゲー 抗ｉｌ−１治療に関する新しい適応症
JP2011515068A (ja) 2007-11-08 2011-05-19 ノバルティス アーゲー 慢性／硬化性同種移植腎症に対する遺伝子発現シグネチャー
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US9752191B2 (en) 2009-07-09 2017-09-05 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012012737A2 (en) 2010-07-23 2012-01-26 The University Of Toledo Stable tregs and related materials and methods
CN103608349A (zh) 2011-06-27 2014-02-26 诺瓦提斯公司 四氢-吡啶并-嘧啶衍生物的固体形式和盐
MX2014000338A (es) 2011-07-08 2014-05-01 Novartis Ag Derivados de pirrolo-pirimidina novedoso.
WO2013057711A1 (en) 2011-10-21 2013-04-25 Novartis Ag Quinazoline derivatives as pi3k modulators
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
WO2013148638A2 (en) * 2012-03-26 2013-10-03 Ep Pharma, Inc. Compositions and methods related to inhibitors of jak kinase
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015179773A1 (en) 2014-05-22 2015-11-26 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
SG11201600028YA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
EP3134395B1 (en) 2014-04-24 2018-01-31 Novartis AG Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EA032075B1 (ru) 2014-04-24 2019-04-30 Новартис Аг Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104090115B (zh) * 2014-07-10 2016-01-13 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
WO2020234779A1 (en) 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA712187A (en) * 1965-06-22 J. C. Buisson Paul 2-(2'-oxo-1'-cyclododecyl) acetic acid, the salts thereof, and process of preparing same
FR1466205A (fr) * 1960-04-01 1967-01-20 Chimie Atomistique Acide 1-cétocyclododécyl-2-acétique, ses sels et leur procédé de préparation
AU566673B2 (en) * 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
CA2392554A1 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2326952A1 (en) * 2000-11-27 2002-05-27 The Hospital For Sick Children T cell protein tyrosine phosphatase

Also Published As

Publication number Publication date
ZA200504163B (en) 2007-03-28
US7928062B2 (en) 2011-04-19
CA2506432A1 (en) 2004-06-24
ECSP055843A (es) 2005-11-22
AU2003297740A2 (en) 2004-06-30
HUP0500844A2 (en) 2007-08-28
NZ540427A (en) 2008-04-30
EP1578411A1 (en) 2005-09-28
US20080167220A1 (en) 2008-07-10
KR20050084224A (ko) 2005-08-26
NO20052497L (no) 2005-09-02
US7365096B2 (en) 2008-04-29
MXPA05006133A (es) 2006-03-09
JP2006514021A (ja) 2006-04-27
US20050203177A1 (en) 2005-09-15
CN1747729A (zh) 2006-03-15
RU2005121672A (ru) 2005-11-20
PL376844A1 (pl) 2006-01-09
NO20052497D0 (no) 2005-05-24
AU2003297740A1 (en) 2004-06-30
WO2004052359A1 (en) 2004-06-24
EP1578411A4 (en) 2007-05-02
AU2003297740B2 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
BR0317099A (pt) Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
SV2003001148A (es) Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv
EA199700280A1 (ru) Ингибиторы протеинкиназы с
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
BR0312464A (pt) Inibidores de tirosina quinases
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
BR0014973A (pt) Heterociclos de nitrogênio bicìclico de alquilamino substituìdo como inibidores de proteìna quinase p38
MX9308199A (es) Inhibidores de enzima.
BR0306785A (pt) Deazapurinas e seus usos
EA199800119A1 (ru) Ингибиторы адгезии клеток
BRPI0514102B8 (pt) composto para inibição da enzima de proteassoma e composição farmacêutica compreendendo dito composto
EA200001176A1 (ru) Гетероциклические ингибиторы p38
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
AR003140A1 (es) Nuevos compuestos utiles para inhibir las interacciones de las tirosinaquinasas/proteinas adaptadoras, composiciones farmaceuticas que lascontienen y metodos de aplicacion de dichos compuestos para inhibir dichas interacciones.
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
Schroecksnadel et al. Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
AR024138A1 (es) Inhibidores de la proliferacion celular
ATE425142T1 (de) Inhibitoren von c-jun n-terminal kinasen (jnk)
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
BR0304963A (pt) Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
ES2171743T3 (es) Derivados de amidinas e isotioureas como inhibidores de la enzima sintasa de oxido nitrico.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE(S),

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.